Back to News
Market Impact: 0.35
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
Source: zacks.com
Corporate Guidance & OutlookHealthcare & BiotechCompany FundamentalsProduct Launches
CDNA raised its 2026 revenue and profit outlook, citing accelerating demand for transplant testing and growth in NavDx. The company also plans to launch new molecular diagnostics in 2027; the article provides no revised figures or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
CDNA0.75
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge